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INTRODUCTION
The Rh D blood-group antigen (often described as the ' rhesus D antigen') is of major clinical importance. The antigen has been shown to be associated with a red-cell membrane polypeptide of Mr 30000-32000 (Gahmberg, 1982; Moore et al., 1982 ; denoted here as the 'D30 polypeptide'); however, the structure of the antigen remains unknown. Studies of membranes from the red cells of rare individuals who lack all of the antigens of the Rh blood-group system (Rhn.11 membranes) have suggested that the D polypeptide is part of a complex involving several other polypeptides (Moore & Green; Avent et al., 1988) . Immunoprecipitation experiments using anti-D antibodies have shown that a glycoprotein of Mr 45000-100000 (denoted here 'D50 polypeptide') co-precipitates with the D30 polypeptide (Moore & Green, 1987) . Similar experiments using a murine monoclonal antibody (R6A) have shown that two further polypeptides, which also co-precipitate, appear to be deficient in Rhnull cells. Both polypeptides are glycosylated and have apparent Mr values of 31000-34000 (denoted here 'R6A32 polypeptide') and 35000-52000 (denoted here 'R6A45 polypeptide'; Ridgwell et al., 1983; Avent et al., 1988) . Two glycoproteins of similar Mr are immunoprecipitated by both anti-c and anti-E antisera (Moore et al., 1982; Moore & Green, 1987) . Rhnull red cells are deficient in two further polypeptides defined by a murine monoclonal antibody, BRIC 125, and by anti-LWab antibodies (Moore, 1983; Mallinson et al., 1986; Avent et al., 1988) . The BRIC 125 polypeptide is a glycoprotein of Mr 47000-52000, and the LW polypeptide(s) is a glycoprotein of Mr 40000-47000. There is further evidence that the polypeptide carrying the Rh blood-group antigens may form a complex with the minor red-cell membrane sialoglycoprotein 4 (synonym glycophorin B; Dahr et al., 1987) .
We report here the results of amino-acid-sequence studies on the polypeptides precipitated by anti-D and R6A and show that the D30 polypeptide and the R6A32 polypeptide have the same sequences at their N-termini. The D50 polypeptide and the R6A45 polypeptide also have the same sequences at their N-termini, but these sequences are quite distinct from those of the D30 polypeptide and the R6A32 polypeptide.
MATERIALS AND METHODS Purification of the anti-Rh D and R6A binding polypeptides Polypeptide material was purified essentially by a scaled-up form of the immunoprecipitation method of Moore et al. (1982) , with the following modifications. § To whom correspondence and reprint requests should be sent.
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Washed erythrocytes (100-200 ml) (Rh phenotype CDe) were incubated with either 1500 ml ofculture supernatant containing approx. 10 jg of IgGJ/ml (human monoclonal anti-D (Kumpel et al., 1988) or 5-10 ml of murine ascitic fluid (BRIC 69 or BRIC 207). BRIC 207 was produced and characterized as described for BRIC 69 (Avent et al., 1988 Polypeptide material was then electroeluted from the gel slices essentially as described by Hunkapiller et al. (1983) , dialysed against 0.1 % (w/v) SDS, and then against water at 4 'C. Any remaining buffer salts were then removed by a single-solvent precipitation of the protein sample (Wessel & Flugge, 1984 RESULTS AND DISCUSSION N-Terminal amino acid sequences of the D30 and D50 polypeptides The D30 and D50 polypeptides were purified by SDS/ polyacrylamide-gel electrophoresis of immunoprecipitates obtained from radioiodinated D-positive red cells using human monoclonal anti-D. The samples were not reduced before electrophoresis. The D30 polypeptide was detected by its radioactivity, whereas the D50 polypeptide was detected by Coomassie Blue staining of samples run in parallel. Fig. l(c) shows Coomassie Blue-stained gels of a typical immunoprecipitate. Amino acid analysis of the purified D30 polypeptide showed that it was obtained in a yield of 7.5 % on the basis of the assumption that there are 30000 D-antigen sites per red cell (HughesJones et al., 1971) . The N-terminal amino acid sequences of both the D30 and D50 polypeptides are shown in Fig.  2(a) . The sequence of the D30 polypeptide was obtained in lower-than-expected yield (estimated to be 20 %), but was obtained up to residue 32. The low yield suggests that the N-terminus of the D30 polypeptide is partially blocked. Two other groups have reported similar amino acid sequence studies on the D30 polypeptide and also obtained low sequencing yields; however, they only reported sequence up to residues 16 and 21 respectively (Bloy et at., 1988; Saboori et at., 1988) . The sequence contains tyrosine residues at positions 4 and 28, but these do not contain any 125I radioactivity, suggesting that they are not accessible to radioiodination by lactoperoxidase in the intact red cell. The N-terminus of the sequence from residues 1 to 10 has a polar character, suggesting that it is exposed at a membrane surface. The lack of radioactivity at tyrosine-4 and the presence of a cluster of basic residues at positions 3, 6, 9 and 10 suggest that this region of the protein is exposed to the cytoplasm. A segment of 19 hydrophobic residues follow residue 10, interrupted in the centre by glutamic acid-20. This region may represent a membrane-spanning region.
The N-terminal sequence of the D50 polypeptide was obtained in almost quantitative yield and is shown in Fig. 2(a) . The sequence is clearly different from that of the D30 polypeptide. The N-terminal sequence up to valine-24 is comprised of hydrophobic amino acids, except for glutamic acid-13. The region to valine-24 is of sufficient length to span the membrane and is followed on the C-terminal side by a sequence containing polar amino acids which are likely to be located at a membrane surface. N-Terminal sequence of the R6A32 and R6A45 polypeptides Although these polypeptides were first defined by using monoclonal antibody R6A (Ridgwell et al., 1983; Avent et al., 1988) , other monoclonal antibodies of the same specificity [BRIC 69 (Avent et al., 1988) and BRIC 207 (see the Materials and methods section)] have subsequently been made which are more suitable for preparative immunoprecipitation. Fig. l(a) shows the results of immunoprecipitation experiments from radioiodinated red cells using BRIC 69 (Fig. le) and BRIC 207 (Fig. lg) and, on a preparative scale, from unlabelled red cells [BRIC 69 (Fig. lb) ]. The R6A32 and R6A45 polypeptides were purified after SDS/polyacrylamidegel electrophoresis of immunoprecipitates obtained from red cells. The N-terminal sequences of the R6A32 and R6A45 polypeptides showed no differences from those of the D30 and D50 polypeptides respectively (Fig. 2b) . Residue 2 of the R6A45 polypeptide was shown to be cysteine by using the S-pyridylethylation method (Amons, 1987) .
Although the D30 and R6A32 polypeptides have the same N-terminal sequences, they are clearly different molecules. The differences in Mr between the two components has been shown to be due to the presence of an N-glycan on the R6A32 polypeptide, since treatment of this polypeptide with an endoglycosidase F preparation decreases its Mr to that of the D30 polypeptide (Avent et al., 1988) . It is not clear whether this glycosylation difference is due to amino acid sequence differences between the polypeptides or a reflection of conformational factors which allow glycosylation of one polypeptide and not the other. The fact that D-negative red cells react with the R6A group of monoclonal antibodies (Anstee & Edwards, 1982) suggests a structural difference between the two polypeptides. Moore & Green (1987) have shown that antisera to the c and E antigen of the Rh system immunoprecipitate a component which is of similar molecular size to the R6A32 polypeptide. It is possible that these antigens are carried on the R6A32 polypeptide.
A similar close sequence relationship exists between the D50 polypeptide and the R6A45 polypeptide. The two molecules clearly differ in molecular size and also differ in their ability to be radioiodinated (compare Figs. be Protein-sequence studies on Rh-related polypeptides (Avent et al., 1988) . The D50 polypeptide is also glycosylated (Moore & Green, 1987) , but the Mr of the deglycosylated form has not been determined. As with the D30 and R6A32 polypeptides, the origin of differences between the R6A45 and the D50 polypeptides remains to be determined.
Sequence relationships between Rh-related polypeptides Comparison of the N-terminal sequences of the D30 and R6A32 polypeptides with that of the D50 and R6A45 polypeptides suggests that they may be homologous in their putative N-terminal membrane-spanning regions (Fig. 2c) . Homologies in membrane-spanning regions have to be treated with caution, because of the restricted set of amino acids found in these domains. However, search of the National Biomedical Research Foundation and the Swissprot protein sequence data bases with the putative membrane-spanning regions of either of the two groups of proteins examined here did not reveal any other sequence with the degree of homology which is apparent in Fig. 2(c) . The relatedness of these proteins in their putative membrane-spanning regions provides a possible explanation for the association of D30 with D50, and R6A32 with R6A45, during co-precipitation. One of the other components deficient in Rhnull cells, the BRIC 125 polypeptide (Avent et al., 1988) , was also purified by immunoprecipitation and gel electrophoresis. Three attempts to obtain an N-terminal sequence for this polypeptide failed, suggesting that it has a blocked Nterminus. This supports other evidence (Avent et al., 1988) that the BRIC 125 polypeptide is distinct from the other polypeptides discussed here.
Concluding remarks
It has been assumed in previous studies that the D30 and R6A32 polypeptides express the epitopes recognized by anti-D antibodies and monoclonal antibodies of the R6A group respectively. The results obtained by Moore & Green (1987) and those described here clearly indicate that each of these antibodies immunoprecipitate two different polypeptides. Whether or not these epitopes are present on one or both of the components, or are dependent upon the association of the two components, remains to be determined.
